The molecular mechanism of antimony-resistant Leishmania donovani (Sb R LD)-driven up-regulation of IL-10 and multidrug-resistant protein 1 (MDR1) in infected macrophages (Mϕs) has been investigated. This study showed that both promastigote and amastigote forms of Sb R LD, but not the antimony-sensitive form of LD, express a unique glycan with N-acetylgalactosamine as a terminal sugar. Removal of it either by enzyme treatment or by knocking down the relevant enzyme, galactosyltransferase in Sb R LD (KD Sb R LD), compromises the ability to induce the above effects. Infection of Mϕs with KD Sb R LD enhanced the sensitivity toward antimonials compared with infection with Sb R LD, and infection of BALB/c mice with KD Sb R LD caused significantly less organ parasite burden compared with infection induced by Sb R LD. The innate immune receptor, Toll-like receptor 2/6 heterodimer, is exploited by Sb R LD to activate ERK and nuclear translocation of NF-κB involving p50/c-Rel leading to IL-10 induction, whereas MDR1 up-regulation is mediated by PI3K/Akt and the JNK pathway. Interestingly both recombinant IL-10 and Sb R LD up-regulate MDR1 in Mϕ with different time kinetics, where phosphorylation of PI3K was noted at 12 h and 48 h, respectively, but Mϕs derived from IL-10 −/− mice are unable to show MDR1 up-regulation on infection with Sb R LD. Thus, it is very likely that an IL-10 surge is a prerequisite for MDR1 up-regulation. The transcription factor important for IL-10-driven MDR1 up-regulation is c-Fos/c-Jun and not NF-κB, as evident from studies with pharmacological inhibitors and promoter mapping with deletion constructs. visceral leishmaniasis | antimony resistance | glycoconjugate | antimony efflux K ala-azar or visceral leishmaniasis, which is caused by the protozoan parasite Leishmania donovani (LD), is (re)emerging and spreading worldwide, essentially because of humanmade and environmental changes, immunosuppression, and drug resistance (1, 2) . To combat the disease, organic pentavalent antimonials were introduced in the Indian subcontinent almost 9 decades ago (3) with dramatic clinical success. However, the toxicity, together with the high treatment failure rate (up to 65%) and the emergence of resistance in Bihar State, India, made the drug obsolete in the Indian subcontinent (4, 5) . Nevertheless, it is still used as a first-line treatment in Africa and Latin America (6) . Interestingly, 78% of the recent clinical isolates from the hyperendemic zone of Bihar State still showed in vitro resistance to antimonials (7) , which might be explained by an increased fitness of the corresponding parasites (8) .
Recently, we have demonstrated three unique characteristics of antimony-resistant LD (Sb R LD). First, it shows a higher concentration of terminal glycoconjugates (N-acetylgalactosamine residues) on its surface than antimony-sensitive LD (Sb S LD) (7) .
Second, on infection of macrophages (Mϕs), Sb R LD induces a surge of IL-10 (7, 9) . Third, we also observed that Sb R LD modulates host cells to overexpress the ATP-binding cassette (ABC) transporters multidrug resistance-associated protein 1 (MRP1) and multidrug-resistant protein 1 (MDR1), which results in the efflux of Sb, thus leading to its inability to clear intracellular parasites (7, 10) . However, the link between these three observations, as well as the mechanism by which Sb R LD modulates IL-10 and MDR1 induction from host cells, is still not clear.
In present study, we explore how Sb R LD and Sb S LD are being scrutinized by the innate immune cells and the possible bearing of this on the outcome of pathogenesis. We show that Sb R LD, with its unique glycans, differentially modulates the innate immune receptor, leading to IL-10 induction and subsequent MDR1 up-regulation in host cell. We decipher the cascade of molecular events likely involved in the regulation of these phenomena and propose a model for the interaction between antimonial resistant parasites and their host cell.
Results

Sb R LD Drives Host Mϕs to Produce IL-10 Through Their Terminal
Glycoconjugates. To ascertain the role of terminal N-acetylgalactosamine in IL-10 induction, promastigotes of Sb R LD (BHU575/BHU138) and Sb S LD (AG83) were subjected to galactosidase treatment. It was observed that the galactosidasetreated Sb R LD induced significantly less IL-10 production (P < 0.0001; two-to 2.5-fold) from Mϕs than its untreated counterpart ( Fig. 1A) . On the other hand, on infection with Sb S LD, IL-10 production was low and remained unaltered after galactosidase treatment.
Galactosyltransferase (GalT) is the key enzyme that adds up galactose residues on glycans (11) . We generated GalT knockdown (KD) Sb R LD (BHU138 KD/BHU575 KD): A significant decrease in the expression of GalT gene and the surface expression of the N-acetylgalactosamine residues was verified by RT-PCR and flow cytometry, respectively ( Fig. S1 A and B) .
Infection of Mϕs with KD Sb R LD resulted in about two-to threefold lower IL-10 levels (P < 0.0001) compared with WT Sb R LD (Fig. 1B ). However, the basal level of IL-12 production remained unaltered regardless of the nature of the infecting parasites ( Fig. 1B) .
To verify if the observations described here were stage-specific, we repeated them with animal-derived amastigotes. We found that the amastigotes of Sb R LD, like the corresponding promastigotes, expressed a significantly higher amount of N-acetylgalactosamine residue (P < 0.0001; threefold) on their surface (lectin binding study; Fig. S1C ) and modulated host Mϕs to produce a higher amount of IL-10 (P < 0.0001; 2.5-to threefold) compared with Sb S LD (Fig. S1D ).
Finally, to determine that the difference in IL-10 induction is due to a quantitative difference in the cell surface glycan rather than intracellular parasite number, Mϕs were treated with the lysate of Sb R LD, Sb S LD, or KD Sb R LD normalized against the number of parasites and also in terms of their protein content, and the resulting IL-10 production was measured. It was observed that Mϕs incubated with Sb R LD lysate produced significantly higher levels of IL-10 (P < 0.0001; two-to threefold) compared with those incubated with either Sb S LD or KD Sb R LD (Fig. 1C ).
Terminal Glycoconjugates Promote the Infectivity of Sb R LD. To determine the role of terminal glycoconjugates, if any, on in vitro infectivity, Mϕs were infected with Sb R LD, KD Sb R LD, or Sb S LD, and at 24-h time point, the intracellular parasite number was determined. After 24 h, the number of amastigotes per 100 Mϕs (P < 0.001; 1.5-fold) was significantly higher on infection with Sb R LD compared with infection with KD Sb R LD and Sb S LD ( Fig. S2 ).
To verify if the same was occurring in an in vivo model, BALB/c mice were infected with the different parasites, and the hepatic as well as splenic parasite load was determined after 3 wk. The parasite load was significantly higher in mice infected with Sb R LD compared with Sb S LD or KD Sb R LD: (i) two-to 2.5-fold ratio (P < 0.001) in the liver ( Fig. 1D ) and (ii) seven-to eight-fold ratio (P < 0.0001) in the spleen (Fig. 1E ). There was significantly higher IL-10 production from the whole splenocytes (P < 0.001; 1.5-to twofold) of Sb R LD-infected mice when stimulated with the corresponding soluble leishmanial antigen (SLA) but not in mice infected with either Sb S LD or KD Sb R LD (Fig. 1F ).
Sb R LD Exploits Toll-Like Receptor 2 but Not Toll-Like Receptor 4 to
Induce IL-10 Production from MΦs. LD infection in THP-1 is reported to cause up-regulation of IL-10 by exploiting Toll-like receptor 2 (TLR2) immune receptors (12) . To establish the role of TLR2 in the outcome of Sb R LD infections, we compared the results obtained with Mϕs derived from C57BL/6 mice, TLR2 −/− mice, or C3He/J mice (TLR4 −/− ). On infection with Sb R LD, we found that the parasite load was two-to threefold lower (P < 0.001) in Mϕs from TLR2 −/− than in C57BL/6 animals, whereas the difference was not significant with Sb S LD (Fig. S3A ). In contrast, there was no significant difference in parasite load when Mϕs derived from C57BL/6 and TLR4 −/− animals were infected either with Sb R LD or Sb S LD (Fig. S3A ). In terms of IL-10 production, we found about a threefold (P < 0.0001) reduction when TLR2 −/− Mϕs were infected with Sb R LD compared with Sb S LD; this was not the case with TLR4 −/− Mϕs (Fig.  S3B ). This was not due to a generalized defect, because LPS (an agonist for TLR4)-driven IL-10 production was comparable between C57BL/6-derived and TLR2 −/− -derived Mϕs (Fig. S3B , Inset). Furthermore, Sb R LD-mediated IL-10 production was significantly reduced (P < 0.0001) in the case of BALB/c Mϕs preincubated with anti-TLR2 and anti-TLR6 Abs, but preincubation with anti-TLR1 Ab had no effect (Fig. S3C ). The coimmunoprecipitation experiment further revealed the involvement of TLR2/6 in the case of Mϕs infected with Sb R LD ( Fig. S3D ), indicating that heterodimerization of TLR2/6 might be critical for Sb R LD-mediated IL-10 production. Altogether, these findings demonstrate that Sb R LD exploits TLR2/6 heterodimer to induce IL-10 production from Mϕs.
Sb R LD-Driven IL-10 Production Is Dependent on NF-κB. Among the downstream signaling molecules of TLRs, ERK (13), PI3K (14) , and NF-κB (15) have been reported to regulate IL-10 production. To identify the most likely signaling molecule in Sb R LD-driven IL-10 production, Mϕs were treated with a series of inhibitors before infection with Sb S LD or Sb R LD. We observed that Sb R LD-driven IL-10 production was largely compromised (P < 0.0001; three-to fivefold) in the case of Mϕs pretreated with ERK or NF-κB inhibitor (PD98059, U0126, and BAY110782, respectively; Fig Together, these results demonstrate that Sb R LD-induced IL-10 production by Mϕs is NF-κB dependent.
Mapping of IL-10 Promoter. There are three potential NF-κB binding sites at the positions −46/−55, −583/−593, and −917/ −927 of IL-10 promoter, defined as site I, site II, and site III, respectively ( Fig. S4A ). To identify the promoter site involved in the Sb R LD-driven IL-10 induction, we transfected Mϕs with several constructs (truncated or not) and assessed luciferase activity on Sb R LD stimulation. The truncated promoter constructs containing site I (−46/−55) and site III (−917/−927) were unable to show enhanced luciferase activity (P < 0.0001; threeto fourfold) under Sb R LD stimulation, in contrast to the untruncated construct ( Fig. S4B ). However, the IL-10 promoter construct carrying site I has been reported to show luciferase activity on LPS stimulation, which indicates that a specific stimulus might result in differential modulation of the host promoter (16) . Moreover, compared with the WT plasmid carrying the IL-10 promoter construct (1.57 kb), the deleted mutant (Mut) IL-10 promoter construct generated by deleting site II (−583/−593) elicited significantly lower luciferase activity (P < 0.0001; four-to fivefold) in transfected cells when infected with Sb R LD (Fig. S4C ). This observation indicated that the sequence −583/−593 (site II) is critical for NF-κB-mediated transcriptional activation of the IL-10 gene under Sb R LD stimulation.
Characterization of NF-κB Subunits. To determine the NF-κB subunits involved in IL-10 promoter activity, a ChIP assay was performed. Immunoprecipitation with acetylated H3, p50, c-Rel, and p65 Abs followed by PCR amplification revealed that p50 and c-Rel, but not p65, were bound to site II (−583/−593) when infected with Sb R LD but not with Sb S LD (Fig. 3A ). This observation was further substantiated by Western blot analysis. There was detectable expression of phosphorylated p50 and c-Rel in the nuclear fraction when Mϕs were infected with Sb R LD but not with Sb S LD, although cytoplasmic expression of whole p50 and c-Rel was almost equivalent on infection with all strains (Fig. 3B ). Finally, specific binding of NF-κB complexes consisting of p50 and c-Rel subunits to the sequence −583 GGGGTT-TCCT −593 (site II) in Mϕs infected with Sb R LD was confirmed with EMSA using murine IL-10 probes containing the WT sequence −583 GGGGTTTCCT −593 (WT mIL-10 probe) or a mutant sequence −583 CTCTTTTAAT −593 (Mut mIL-10 probe) ( Fig. 3C ). Furthermore, supershift analysis with Abs for p50, c-Rel, and p65 revealed that a supershift occurs only in the presence of p50 and c-Rel Abs but not with p65 Ab (Fig. 3D ). Altogether, these results demonstrate that Sb R LD infection specifically modulates site II (−583/−593) of IL-10 promoter to induce p50/c-Rel binding, thereby initiating IL-10 transcription.
Sb R LD-Induced MDR1 Overexpression Is Dependent on IL-10. To find out the relation, if any, between IL-10 production and overexpression of a host cell's MDR1, Mϕs were incubated with different concentrations of recombinant IL-10 (rIL-10). We found that MDR1 expression occurred in a dose-dependent manner ( Fig. S5A ), whereas an unrelated cytokine like rIL-2 failed to show any effect. In addition, MDR1 expression was significantly reduced in the presence of Ab to IL-10 (P < 0.001; threefold) ( Fig S5A, Inset) . The link between IL-10 and MDR1 expression was further substantiated using confocal microscopy. We found that incubation with rIL-10 or infection with Sb R LD, but not with Sb S LD, showed enhanced expression of MDR1 ( Fig. S5B ). Altogether, the results indicate a role of IL-10 in host MDR1 overexpression. MDR1 as an Effective Efflux Pump. Because our results indicated that the surface glycans of Sb R LD induce IL-10-mediated MDR1 overexpression in host cells, we wanted to determine the susceptibility of KD Sb R LD to sodium stibogluconate (SSG). Mϕs were infected with Sb R LD, Sb S LD, or KD Sb R LD, and intracellular parasite number was determined in the presence or absence of SSG. As expected, there was a significant reduction (P < 0.0001; fiveto sixfold) in intracellular parasite number in Mϕs infected with Sb S LD in the presence of SSG. Mϕs infected with KD Sb R LD also showed an increased responsiveness (P < 0.001; two-to 2.5-fold) toward SSG compared with Sb R LD ( Fig. S5C ). Second, using an Rh123 efflux assay, we demonstrated an efflux of Rh123 when Mϕs were infected with Sb R LD but not with Sb S LD or KD Sb R LD (Fig. S5D ). Moreover, rIL-10 treatment showed a gradual decrease in Rh123 retention in normal Mϕs. In contrast, incubation with an increasing concentration of rIL-2 did not alter Rh123 level (Fig. S5E ). Altogether, these findings showed that the surface glycans of Sb R LD may have a role in IL-10-mediated Sb resistance of the parasite in host cells.
Previous reports showed that the MDR1 up-regulation of Mϕs is mediated by the PI3K and Jun kinase pathways (17, 18) . To determine the pathway involved in MDR1 up-regulation, pharmacological inhibitors of PI3K, JNK, NF-κB, and ERK were used. From flow cytometric analysis, it was evident that all these pharmacological inhibitors except BAY110782 (inhibitor of NF-κB) and SB204580 (inhibitor of p38MAPK) could significantly abrogate (P < 0.001; two-to fourfold) rIL-10-mediated MDR1 overexpression ( Fig. S6A ). To validate this observation, Mϕs were either infected with Sb R LD (BHU575) or treated directly with rIL-10 and Western blot analysis was performed. As shown here, infection with Sb R LD induced degradation of ΙκB proteins, corresponding to enhanced IKKα/β phosphorylation; this was not the case with Mϕs directly treated with rIL-10 ( Fig.  S6B ). Therefore, we can conclude that rIL-10-induced MDR1 expression in Mϕs is independent of NF-κB and p38MAPK.
Molecular Events of IL-10-Dependent MDR1 Up-Regulation. To determine signaling molecules eventually leading to MDR1 upregulation, Mϕs were infected with either Sb R LD or Sb S LD or treated with rIL-10 (200 pg/mL) for different periods of time (6, 12, 18, 24 , and 48 h). When Mϕs were infected with Sb R LD, the IL-10 level showed a slight increase at 18 h, peaked at 24 h (P < 0.0001; four-to sixfold), and remained unaltered until 48 h ( Fig.  4A ), whereas MDR1 expression continuously increased until reaching a maximum at 48 h (P < 0.001; 2.5-to threefold) ( Fig.  4B ). On the other hand, rIL-10 driven MDR1 up-regulation was faster and reached a peak (P < 0.0001; 2.5-to threefold) at 12 h posttreatment. Based on this observation, we chose two time points, early (12 h) and late (48 h), for further investigation. Western blot analysis revealed that at 12 h, rIL-10 could induce significantly higher expression of p-PI3K, p-Akt, and p-JNK, whereas Sb R LD failed to show expression of any of these molecules. It has been reported previously that phosphorylation of JNK leads to activation of different activator protein-1 (AP-1) subunits (19) . Interestingly, our result also showed activation of AP-1 (c-Fos and c-Jun; P < 0.001) on rIL-10 treatment at 12 h, whereas other AP-1 subunits like Fra-1, Jun B, and Jun D were absent in the nuclear extract irrespective of the nature of the infection or rIL-10 treatment. However, at 48 h, Sb R LD could significantly up-regulate PI3K/JNK pathway intermediates, which were inhibited (P < 0.001) in the presence of neutralizing α-IL-10 ( Fig. 4C ). Finally, to confirm that IL-10 is indeed responsible for MDR1 up-regulation, Mϕs from IL-10 −/− mice and their WT counterparts were infected with either Sb R LD or Sb S LD for 48 h. Cells were then analyzed for their surface MDR1 status by flow cytometry. Mϕs from IL-10 −/− failed to induce MDR1 (P < 0.0001; twofold) on infection with Sb R LD ( Fig. 4D ), although an equivalent amount of IL-12 production was observed from both IL-10 −/− and C57BL/6 Mϕs, indicating the direct role of IL-10 in MDR1 up-regulation ( Fig. 4D, Inset) . Altogether, these findings showed that in contrast to IL-10 upregulation, which is dependent on NF-κB, MDR1 overexpression is dependent on the PI3K/JNK pathway.
Characterization of MDR1 Promoter. A potential AP-1 binding site ( −123 TGAGTCA −117 , defined as site A) on the murine MDR1 promoter has previously been reported (20) (Fig. 5A ). To determine whether site A is indeed modulated by IL-10 to induce MDR1, the MDR1 whole-promoter +37/−154 (191 bp, WLpGL3-MDR1) with site A, and the MDR1 truncated promoter +37/−116 (153 bp, trun-pGL3-MDR1) lacking site A were cloned in a pGL3 basic vector and a luciferase assay was performed. Unlike the total promoter construct (191 bp), the truncated promoter construct (153 bp) failed to show enhanced luciferase activity (P < 0.001; four-to fivefold) when stimulated with rIL-10 (200 pg/mL) or Sb R LD (Fig. 5B ). From site-directed mutagenesis of site A, it was also observed that compared with the WT plasmid (pGL3-MDR1), the deletion construct (pGL3-MDR1ΔAP1) showed compromised luciferase activity (P < 0.0001; 10-to 12-fold) in transfected cells stimulated with rIL-10 (200 pg/mL) ( Fig. 5C ). Furthermore, specific DNA binding of AP-1 to the sequence −123 TGAGTCA −117 of murine MDR1 promoter in response to IL-10 was confirmed via EMSA using murine MDR1 probes containing the WT sequence −123 TGAGT-CA −117 (WT MDR1 probe) or the mutant sequence −123 ACAG-TGT −117 (Mut MDR1 probe) ( Fig. 5D ) and via supershift analysis ( Fig. 5E ) using Ab for c-Fos, c-Jun, and Fra1. These results demonstrated that cFos/cJun binds specifically with site A of the MDR1 promoter in an IL-10-dependent manner, and thereby causes its overexpression.
Discussion
Research on Leishmania drug resistance has focused so far essentially on the parasite itself and the direct molecular adaptations within the parasite (5) . Recent studies have shown that Leishmania is a master of manipulation of its host cell; conse-quently, mechanisms of drug resistance should also be addressed at the level of the infected Mϕ. In a previous report, we showed that Sb R LD could interfere with the signaling system of the Mϕ and counter its oxidative burst (21) . In the present study, we explored another domain of the parasite/host cell interaction and deciphered the complex interaction between Sb R LD-specific parasite surface glycoconjugates, infectivity and IL-10 induction, overexpression of Mϕ MDR1, and efflux of antimonials from the host cell.
We first focused on the terminal glycoconjugates and showed (i) that they were overexpressed in amastigote stages, as well as in promastigotes of Sb R LD, and (ii) that this overexpression was correlated with IL-10 induction ( Fig. 1 and Fig. S1 ). Then, two independent experiments (galactosidase treatment and GalT KD Sb R LD) demonstrated the role of these glycoconjugates in IL-10 induction ( Fig. 1 A and B) . The glycan with terminal N-acetylgalactosamine is not yet identified, and it is uncertain if it is the molecule solely responsible for IL-10 generation. However, we know already that it is not lipophosphoglycan (LPG; one of the major surface components in Leishmania). Indeed, (a) unlike LPG, it is expressed both in amastigotes and promastigotes, and (b) treatment of Mϕs with purified LPG does not induce IL-10 but does induce TNF-α as reported by others (22) . Concomitant to IL-10 induction, Sb R LD also caused higher parasite burdens in vitro and in vivo ( Fig. 1 C and D) . There are previous reports that patients who have kala-azar and harbor Sb R LD show a much higher parasite burden and much greater IL-10 production compared with those harboring Sb S LD (23, 24) . This phenomenon of increased parasite burden in Sb R LD-mediated infection may also be an attribute of the terminal glycoconjugates, as shown by KD experiments. Interestingly, in vivo parasite loads with Sb R LD were much higher in the spleen than in the liver, in agreement with previous reports (25, 26) . The reason for such a huge difference in the splenic parasite load on infection with Sb R LD is not clear at the present time. It is tempting to speculate that the surface glycan of Sb R LD may favor its uptake by the splenic Mϕs. There is a report that the capsular polysaccharide in Streptococcus pneumonia interacts with a specific C-type lectin, which favors its uptake by mouse splenocytes (27) .
It is not surprising that unlike intracellular Sb R LD, KD Sb R LD is more sensitive to SSG-like Sb S LD because it fails to overexpress host MDR1 (Fig. S5C) . It is also possible that the unique glycans of Sb R LD may quench SSG-induced reactive intermediates favoring parasite growth as a consequence of less accumulation of antimonials in Sb R LD-infected Mϕs due to overexpression of MDR1. This attribute appears to be absent in Mϕs infected with Sb S LD or KD Sb R LD, and parasites were killed in response to SSG. It may be recalled that the surface glycocalyx of parasites plays an important role in prevention of SSG-mediated oxidative burst in Mϕs (28) .
Second, we focused on the link between antimonial resistance, IL-10 induction, and MDR1 up-regulation. Our study showed that exogenous IL-10 induces up-regulation of MDR1 in a dosedependent manner, which is inhibited in the presence of α-IL-10 Abs, suggesting that IL-10 may act in an autocrine manner for MDR1 up-regulation ( Fig. S5 A and B) . Furthermore, functional assay with Rh123, a fluorescent substrate for MDR1, which is actively effluxed out from Mϕs either infected with Sb R LD or treated with rIL-10 further supports the notion that Sb R LDdriven IL-10 is the key factor up-regulating MDR1 and causing efflux of SSG ( Fig. S5 D and E) . Kinetic analyses, Western blot studies, and infections of IL-10 −/− Mϕs indicated that IL-10 is a prerequisite for MDR1 up-regulation, and this without any direct involvement of Sb R LD (Fig. 4 ). It has been reported that MDR1 is responsible for drug resistance in cancer (29) . IL-10 overexpression is known to be responsible for chemoresistance in cancer cells (30) or drug unresponsiveness in infected cells (10), but our observation reveals that expression of MDR1 is selectively driven by IL-10.
Third, we characterized the cascade of molecular events likely involved in IL-10 induction and MDR1 up-regulation. Previous reports suggested that activation of ERK is the key step for IL-10 induction (31) . Interestingly, infection with Sb S LD results in the inactivation of host ERK, NF-κB, and JNK, thereby favoring establishment of the parasite (32) . In our study, we also did not observe any activation of ERK or NF-κB in Mϕs infected with Sb S LD, although Sb R LD activates ERK and nuclear translocation of NF-κB involving p50/c-Rel, leading to IL-10 induction, through interaction with IL-10 promoter site II (−583/ −593). Moreover, previous reports have suggested a possible role of PKC in IL-10 induction from Mϕs infected with Sb S LD (AG83) (33) . It is already known that specific stimulations with LPS lead to unique modifications of the IL-10 promoter (15) . There is a report that site I (−46/−55) of the IL-10 promoter binds with NF-κB under LPS stimulation (16) . Our results ( Fig.  3 ) are in agreement with a previous report stating that the p50/c-Rel activated on infection by Leishmania major amastigotes is involved in IL-10 secretion in fresh human monocytes (34) .
Previously, it has been shown that TLR2 can differentially recognize peptidoglycans from Gram-positive and Gram-negative bacteria (35) . Moreover, recent reports suggest that Sb S LD (AG83) may deactivate the host TLR2 signaling pathway (36) . It is not yet conclusive whether the glycans overexpressed in Sb R LD directly interact with TLR2. It is possible that the glycans, as well as TLR2, independently contribute to IL-10 upregulation in the host rather than the glycans interacting directly with TLR2. Earlier reports showed that TLR2 homodimerizes or heterodimerizes with TLR1 or TLR6 (37) . Our results suggest that Sb R LD exploits TLR2/6 heterodimer rather than TLR2/1 heterodimer to induce host IL-10 ( Fig. S3 ). This fits with the previous report that hepatitis C virus induced murine peritoneal Mϕ activation by formation of TLR2/6 heterodimer (38) .
There are reports that the PI3K/Akt pathway influences the expression of ABC transporters, such as MRP1 or MDR1 (18) . Others have demonstrated that IL-10 activates the PI3K pathway, which results in the activation of Akt (39) . With respect to the IL-10-mediated MDR1 up-regulation, we found that it involved (i) activation of the PI3K/Akt pathway, leading to activation of JNK and AP-1 but not NF-κB (Fig. 4) , and (ii) signaling cascade activation of c-Fos and c-jun to translocate and bind to the putative AP-1 binding site on the MDR1 promoter, thus bringing about MDR1 transcription ( Fig. 5 ). Activation of c-Fos and c-Jun to drive MDR1 overproduction in Sb R LD-infected Mϕs seems unique. Indeed, it has been reported previously that in different species of Leishmania, including LD, surface metalloprotease gp63 inactivates all the subunits of the AP-1 transcription factor, because all the subunits, such as c-Fos, c-Jun, Jun B, Jun D, and Fra 1, have putative sites of gp63 cleavage (32) . The contrast, compared with our findings, could be explained by experimental differences between the two studies. Contreras et al. (32) focused on the early stage of infection (earliest at 0.5 h and latest at 3 h), whereas we followed it until 48 h. However, the main explanation for the discrepancy likely resides in the unique nature of the Sb R LD-driven IL-10 induction observed here. This observation probably identifies the expression of AP-1 as a direct effect of IL-10 without any role of input from LD parasites. Mϕs infected with Sb R LD began to express c-Fos/c-Jun at the 48-h time point, when there is already enough IL-10. However, this is abrogated when Mϕs are preincubated with IL-10 neutralizing Abs, further reinforcing the idea of expression of c-Fos/c-Jun as a direct function of IL-10 ( Fig. 4) .
This study reports that the Sb R LD-specific glycans induce IL-10 production from Mϕs, which, in turn, up-regulate host MDR1 and eventually may contribute to drug resistance and increased pathogenicity. It broadens our view of the panel of molecular mechanisms involved in antimonial resistance, highlighting their complementarity. It is remarkable, for instance, that Sb R LD not only pumps out SbIII, the reduced and active form of the drug, through its own efflux pumps but can manipulate the Mϕ to extrude the prodrug SbV through the MDR1 of the host cell (7) . It demonstrates that further studies on drug resistance should definitively not only focus on the parasite but integrate its direct interface, the Mϕ. Finally, it raises concern about the impact of such major molecular adaptations on the outcome of the few available drugs that are implemented in the Indian subcontinent. This is even more concerning, when one is reminded that both Sb and miltefosine exploit the same efflux pump (40) . Further work is required to understand if the increasing treatment failure rate of miltefosine in the Indian subcontinent is the consequence of the heritage of the antimonials (41) . Our study provides molecular insights as to how Sb R LD differentially scrutinizes the innate immune machinery of the host, thereby up-regulating IL-10 and subsequently overexpressing MDR1, giving rise to distinct treatment outcomes.
Materials and Methods
Animals. BALB/c mice and golden hamsters (Mesocricetus auratus) were maintained and bred under pathogen-free conditions. C57BL/6, TLR2 −/− , and C3He/J (TLR4 −/− ) mice were obtained from the Indian Institute of Science, and IL-10 −/− mice were a kind gift from Gobardhan Das (International Center for Genetic Engineering and Biotechnology, New Delhi, India). Use of both mice and hamsters was approved by the Institutional Animal Ethics Committee of the Indian Institute of Chemical Biology. All animal experiments were performed according to the National Regulatory Guidelines issued by Committee for the Purpose of Supervision of Experiments on Animals, Ministry of Environment and Forest, Government of India. (7) , maintained in golden hamsters (42) , were used for this study. Amastigotes were obtained from the spleen of infected hamsters (43) , and they were subsequently transformed into promastigotes and maintained (44) .
Cell Culture and Infection. Peritoneal exudate cells, conveniently named Mϕs, were harvested from BALB/c, C57BL/6, TLR2 −/− , and IL-10 −/− mice as described (7) . Mϕs were plated, maintained, and infected (1:10 multiplicity of infection) with stationary-phase LD promastigotes. Parasite SLA was prepared as described (44) . Parasite lysates from LD promastigotes were generated as described (45), with slight modifications as described in SI Materials and Methods.
Treatment. Parasites were treated with galactosidase (0.2 units) and either fixed or left unfixed before infection. Parasite lysates were also used to treat Mϕs. In some experiments, infected Mϕs were treated with 60 μg/mL SSG as described elsewhere (7) . In other experiments, Mϕs were treated with various pharmacological inhibitors before infection in serum-free medium. Mϕs were treated with rIL-10 Ab (BD Pharmingen) or with αIL-10 Ab (BD Pharmingen), which was preincubated before infection. In other experiments, TLR2 Ab (10 ng/mL), TLR1 Ab (10 ng/mL), or TLR6 Ab (10 ng/mL) was preincubated with Mϕs for 2 h in serum-free medium before infection. In some experiments, Mϕs were stimulated with either FSL-1 (Invivogen) or Pam3CSK4 (Invivogen), both at a concentration of 10 ng/mL for 24 h. All experiments are described in detail in SI Materials and Methods. Transfection. Anti-LdGalT construct and corresponding empty vector pXG-B2863 were transfected into LD promastigotes by electroporation as described elsewhere (46) , and GalT KD parasites (KD Sb R LD) were generated. RAW264.7 cells were grown and transiently transfected with complete IL-10 (1.57 kb) truncated IL-10 (275 or 274 bp), or Mut IL-10 (NF-κB binding site −583/−593), or with complete MDR1 (191 bp), truncated MDR1 (153 bp), or mutant MDR1 (AP-1 binding site −117/−123) promoter constructs. All experiments are described in detail in SI Materials and Methods.
RT-PCR Analysis. Total RNA was isolated from GalT KD, WT, or vector control isolates using the Total RNA isolation kit (Roche Biochemicals) according to the manufacturer's protocol. RNA was stored at −70°C until further use. RT-PCR was performed using specific primers for LdGalT3 and GAPDH following the standard protocol.
Cytokine Measurement. IL-10, IL-12, and TNF-α levels were measured in the supernatant by ELISA (R&D Systems) following the manufacturer's manual.
Dye Uptake and Retention Assay. Rh123 uptake and retention studies were performed fluorometrically as described elsewhere (47) , with slight modifications as described in SI Materials and Methods.
Immunostaining and Flow Cytometry. The expression levels of N-acetylgalactosamine residue in WT as well as KD LD were determined by flow cytometrically using FITC-labeled Dolichos biflorus agglutinin and compared with their mannose levels (specific to Con A lectin) (7) . The levels of expression of MDR1 in infected or treated Mϕs were determined by immunostaining, followed by flow cytometry (Aria II; Becton Dickinson) and/or confocal microscopy (LSM 510; Carl Zeiss), as described elsewhere (10) . Details of the experiment are described in SI Materials and Methods.
EMSA. Nuclear extracts were prepared from Mϕs as described elsewhere (9) . These extracts were incubated with radiolabeled, double-stranded oligonucleotide probes either for murine IL-10 promoter containing WT or mutant NF-κB binding sites, or for MDR1 promoter containing WT or mutant AP-1 binding sites, respectively. Protein-DNA complexes were separated on acrylamide gels. EMSA was performed using a gel shift assay system (Promega) according to the manufacturer's protocol. Supershift experiments were performed as described in SI Materials and Methods.
Western Blot and Coimmunoprecipitation. Cytoplasmic and nuclear protein was prepared, and Western blotting was performed for p50, phospho-p50, and c-Rel (Santa Cruz Biotechnology); pIKKα/β, pIκBα, IκBα, IκBβ, IκBe, pERK1/ pERK2 (Thr202/Tyr204), ERK1/ERK2, p65, pPI-3K/PI-3K, pAKT/AKT, pJNK/JNK, pc-Fos/c-Fos, pc-Jun/c-Jun, β-actin, and histone (Cell Signaling Technology) as described in SI Materials and Methods. Coimmunoprecipitation was performed as described previously (48) using specific TLR2 Ab (Santa Cruz Biotechnology) or unrelated whole-rabbit IgG (Cell Signaling Technology), and blots were probed with Abs against TLR1 (Santa Cruz Biotechnology) or TLR6 (Santa Cruz Biotechnology).
Reporter Assay. Luciferase activity in cell extracts from infected or treated Mϕs was measured using the Dual Luciferase Reporter kit (Promega) according to the manufacturer's protocols, and the luciferase activity was normalized to the level of the protein content.
ChIP Analysis. ChIP assays were performed on infected Mϕs using a ChIP assay kit (Upstate) following the manufacturer's instructions. Details are provided in SI Materials and Methods.
Statistical Variation and Presentation. Each experiment was performed three times, and representative data from one set are presented. Interassay variation was within 10%. Statistical significance between the means of various groups was determined using a two-tailed Student t test. Only P values below 0.05 were considered to be statistically significant. P values <0.001 were considered to be extremely significant (***), P values ranging between 0.001 and 0.01 were very significant (**), P values ranging between 0.01 and 0.05 were significant (*), and P values >0.05 were not significant. Error bars indicate the mean ± SD. Data were analyzed using Prism 5.0 (GraphPad).
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Mukherjee et al. 10 .1073/pnas.1213839110 SI Materials and Methods Cell Culture and Infection and Preparation of Parasite Lysate. Peritoneal exudate cells, conveniently named macrophages (Mϕs), were harvested from BALB/c, C57BL/6, Toll-like receptor 2 −/− (TLR2 −/− ), TLR4 −/− , and IL-10 −/− mice by lavage 48 h after i.p. injection of 2% (wt/vol) soluble starch (SIGMA) (1) . Mϕs were plated on 90-mm tissue culture Petri dishes or in 24-well plates (Nunc) at a density of 1 × 10 7 or 1.5 × 10 6 , respectively, and also on sterile 22-mm square coverslips in 35-mm disposable Petri plates at a density of 1.5 × 10 5 per coverslip in RPMI medium 1640 (SIGMA) supplemented with 10% (vol/vol) heat-inactivated FBS, 100 IU/mL penicillin, and 100 μg/mL streptomycin (GIBCO) (i.e., RPMI complete medium). The cells were left to adhere for 48 h at 37°C under 5% (vol/vol) CO 2 before infection. Mϕs were infected with stationary-phase Leishmania donovani (LD) promastigotes at a ratio of 1:10 for 6 h, washed to remove free parasites, and incubated for another 24 h or 48 h to determine the infection rate. Supernatants obtained from Mϕs infected with stationary-phase LD promastigotes at a ratio of 1:10 for 48 h were subsequently used for ELISA experiments unless otherwise stated. Parasite lysates were prepared as described by Kapler et al. (2) with slight modifications. The protein content of the lysate was estimated, and an equal concentration of the lysate protein was directly used for the experiment without further centrifugation steps.
Treatment. Stationary-phase LD promastigotes were centrifuged at 1,800 × g for 10 min. The supernatant was discarded, and the pellet was resuspended in a minimum volume of PBS and treated with galactosidase (0.2 units; SIGMA) for 1 h at 37°C to remove surface sugar. The parasites were washed and fixed with 1% paraformaldehyde for 15 min and washed five times with cold PBS (3). These paraformaldehyde-treated parasites were then resuspended in complete medium before infecting the Mϕs. In some experiments, Mϕs were treated with 10 μΜ ERK1/2 inhibitor U0126 (4), 20 μΜ PD 98059 (5), 1 μΜ PI3K inhibitor (wortmannin) (6), 20 μΜ ΙκΒ kinase inhibitor BAY 11-7082 (7), 25 μΜ JNK inhibitor SP 600125 (8), or 10 μΜ p38 inhibitor SB 203580 (9) for 45 min before infection in serum-free medium. In some experiments, Mϕs were treated with murine IL-10 (2, 20, or 200 pg/mL) for 12 or 48 h in the presence or absence of 10 μg/ mL αIL-10 Ab/isotype control Ab, which was preincubated for 1 h before infecting the Mϕs. In some experiments, Mϕs were stimulated with LPS (1 μg/mL) and used as a positive control.
Generation of Galactosyltransferase Knockdown Antimony-Resistant LD: Construction of Expression Vectors and Transfection in Leishmania.
The antisense construct of the galactosyltransferase (GalT) gene was generated by PCR amplification of the 1,414-to 1,653-nt region of the phosphoglycan β-1,3 galactosyltransferase 3 gene (LdGalT3) from the genomic DNA of LD parasites using the sense primer 5′-CGGGATCCCTGTGGCAGGAGGCGCTG-CACCACCGCAA-3′ and the antisense primer 5′-TCCCCC-GGGGTCGCTCAAGTACTGTGGCACCTTCAGGTA-3′ and was then cloned in an antisense orientation in the SmaI/BamHI sites of the pXG-B2863 vector (a kind gift from S. M. Beverley, University of Washington, Seattle, WA); this was termed anti-LdGalT. The construct, along with the empty vector pXG-B2863, was transfected into LD promastigotes by electroporation as described previously (2) . Briefly, late-log-phase promastigotes were harvested and washed twice in OPTI-MEM (GIBCO). Cells were then suspended at a density of 1 × 10 8 cells/mL, and 0.4 mL of this was taken into a 0.2-mm ice-chilled electroporation cuvette. Thirty micrograms of plasmid DNA was taken in 100 μL of electroporation buffer and added to the cells. After 10 min on ice, the cells were electroporated with a single pulse by a Bio-Rad Gene Pulsar apparatus using 450-V and 550-μF capacitance. The cells were incubated on ice for a further 5 min and then added to 10 mL of drug-free growth medium. After 24 h of survival, 10 μg/mL G418 was added and kept at 22°C. The transfected cells were monitored visually by microscope, and the drug concentration was increased gradually. Finally, the transfected cells were routinely maintained in medium containing 200 μg/mL G418.
Dye Uptake and Retention Assay. Antimony-sensitive LD (Sb S LD)and antimony-resistant LD (Sb R LD)-infected Mϕs were washed and resuspended (2 × 10 5 cells/mL) in serum-free RPMI, incubated with an optimum concentration (250 ng/mL) of free Rh123 for 32 h, washed, and further incubated in media free of Rh123. In some experiments, Mϕs were incubated with Rh123 for 16 h, after which they were washed and further incubated in Rh123-free medium with an increasing concentration of either recombinant IL-10 (rIL-10) or rIL-2 (2, 20, or 200 pg/mL) for another 2 h. At indicated time points, cells were washed three times in PBS and finally lysed in 0.1% Triton X-100. The intracellular dye concentrations were determined by measuring the fluorescence intensity of the cell lysates.
Flow Cytometry and Confocal Microscopy. Stationary-phase LD parasites (2 × 10 6 cells/mL each), were stained with FITClabeled Dolichos biflorus agglutinin and compared with their mannose level specific to Con A lectin. Samples were subjected to flow cytometry analysis in a FACS Aria II cell sorter (Becton Dickinson). The mean fluorescence intensity was analyzed by FACS DIVA software (Becton Dickinson), and, accordingly, the relative expression of surface sugar was determined. Multidrugresistant protein 1 (MDR1) was stained using a primary anti-MDR1 Ab (Santa Cruz Biotechnology), followed by a secondary FITC-conjugated anti-rabbit whole-IgG molecule (SIGMA). The appropriate isotype control was used for each experiment. Staining was performed 48 h after washing the unpermeabilized infected cells in cold PBS, specifically to check the expression of MDR1 on the host cell surface (10) .
EMSA. DNA probes specific for murine IL-10 promoter containing WT or mutant NF-κB binding sites, represented by the WT mIL-10 probe 5′-GCCCTCTCGGGGTTTCCTTTGGG-3′ and the mutant (Mut) mIL-10 probe 5′-GCCCTCTCCTCTTTTAAT-TTGGG-3′ (NF-κB binding site is underlined, and mutated bases are italicized), respectively, were used. Supershift EMSA was carried out using the following Abs: αp50, αc-Rel (Santa Cruz Biotechnology), and αp65 (Cell Signaling Technology). For the MDR1 promoter, WT or mutant activator protein-1 (AP-1) binding sites, represented by the WT mMDR1 probe 5′-CAA-TAATACTTGAGTCAAGCTGG-3′ and the Mut mMDR1 probe 5′-CAATAATACTACAGTGTAGCTGG-3′ (AP-1 binding site is underlined, and mutated bases are italicized), respectively, were used. Supershift EMSA for the MDR1 promoter was carried out using the following Abs: αc-Fos, αc-Jun, and αFra1 (Cell Signaling Technology). Bands were visualized using a phosphoimager.
Western Blot Analysis. Blots were probed with specific Abs. Binding of secondary HRP-labeled goat anti-rabbit or goat anti-mouse 
Abstract
Background: In an endeavor to find an orally active and affordable antileishmanial drug, we tested the efficacy of a cationic amphiphilic drug, imipramine, commonly used for the treatment of depression in humans. The only available orally active antileishmanial drug is miltefosine with long half life and teratogenic potential limits patient compliance. Thus there is a genuine need for an orally active antileishmanial drug. Previously it was shown that imipramine, a tricyclic antidepressant alters the protonmotive force in promastigotes, but its in vivo efficacy was not reported.
Methodology/Principal Findings: Here we show that the drug is highly active against antimony sensitive and resistant Leishmania donovani in both promastigotes and intracellular amastigotes and in LD infected hamster model. The drug was found to decrease the mitochondrial transmembrane potential of Leishmania donovani (LD) promastigotes and purified amastigotes after 8 h of treatment, whereas miltefosine effected only a marginal change even after 24 h. The drug restores defective antigen presenting ability of the parasitized macrophages. The status of the host protective factors TNF a, IFN c and iNOS activity increased with the concomitant decrease in IL 10 and TGF b level in imipramine treated infected hamsters and evolution of matured sterile hepatic granuloma. The 10-day therapeutic window as a monotherapy, showing about 90% clearance of organ parasites in infected hamsters regardless of their SSG sensitivity.
Conclusions: This study showed that imipramine possibly qualifies for a new use of an old drug and can be used as an effective orally active drug for the treatment of Kala-azar.
Introduction
The disease visceral leishmaniasis or Kala-azar is caused by the protozoan parasite Leishmania donovani (LD) and is widening its base in different parts of the world [1, 2] . Pentavalent antimonial or SSG, which has long been the first line drug, is no longer recommended for use as high levels of resistance in the Indian subcontinent have been reported [3] . Other drugs like miltefosine (hexadecylphosphocholine, a polyene antibiotic) and amphotericin B (an anti-fungal agent) are in current clinical use. As miltefosine is orally active, it offers advantages in terms of reduced hospitalization but cannot be used during pregnancy and lactation [2] . Amphotericin B and its liposomal form are to be administered as an infusion and therefore the patients require hospitalization [4] . Unfortunately, treatment failure cases to miltefosine [5] and amphotericin B [6] are emerging, which raises serious concerns for their future use. There is a genuine need for an orally active and affordable drug for the treatment of relapsed Kala-azar cases.
Imipramine, N-(c-dimethylaminopropyl)-iminodibenzyl HCl, is a tricyclic antidepressant and belongs to the broad class of cationic amphiphilic drugs. The tricycle consists of two benzene rings fused with a seven member heterocycle. Imipramine is FDA (Food and Drug Administration) approved drug for treating depression and paediatric nocturnal enuresis [7] , and is sometimes used off-label to treat chronic pain in combination with other pain medications [8] . The dose range for treating depression is 100-200 mg daily and the recommended use for enuresis is 10-75 mg daily [9] . The selection of imipramine for therapy of experimental visceral leishmaniasis is based on the following past observations by others: (i) the drug alters the proton motive force of LD's membrane [10] , (ii) inhibits trypanothione reductase, an enzyme upregulated in SSG resistant LD parasites [11] , (iii) an effective immunomodulator as it induces the production of TNF-a, an important cytokine for antileishmanial defense [12] , (iv) cationic properties favor its absorption by phagocytic cells and accumulation in phagolysosomal bodies [13] , and (v) its metabolite desipramine is as effective as 
